IRONWOOD PHARMACEUTICALS INC (IRWD)
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
📈 **POSITIVE** • High confidence analysis (90%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business